Ear­li­er this month, Resh­ma Ke­wal­ra­mani took over the reins as Ver­tex Phar­ma­ceu­ti­cals’ CEO — she will now be tasked with grap­pling with crit­i­cism from cost-ef­fec­tive­ness watch­dog ICER, which on Mon­day is­sued a re­port sug­gest­ing that de­spite the health gains of­fered by its suite of cys­tic fi­bro­sis drugs, their prices are far too high to be sus­tain­able for pa­tients and health care sys­tems.

David Rind

“De­spite be­ing trans­for­ma­tive ther­a­pies, the prices set by the man­u­fac­tur­er – cost­ing many mil­lions of dol­lars over the life­time of an av­er­age pa­tient – are out of pro­por­tion to their sub­stan­tial ben­e­fits,” said David Rind, ICER’s chief med­ical of­fi­cer in a state­ment.

The cys­tic fi­bro­sis drugs made by Ver­tex are the first treat­ments that ad­dress the un­der­ly­ing ge­net­ic caus­es of CF, which is char­ac­ter­ized by thick sticky mu­cus in the lungs, di­ges­tive sys­tem and oth­er or­gans that re­duces life ex­pectan­cy. Ver­tex’s med­i­cines tar­get the cys­tic fi­bro­sis trans­mem­brane con­duc­tance reg­u­la­tor (CFTR) gene and are en­gi­neered to cor­rect the mal­func­tion­ing pro­tein it makes.

A lit­tle over 300 dif­fer­ent mu­ta­tions are known to cause CF, and pa­tients typ­i­cal­ly car­ry path­o­gen­ic mu­ta­tions in both copies of the CFTR gene — the most com­mon such mu­ta­tion is F508del. The com­pa­ny’s Orkam­bi and Symke­vi fo­cus on the more com­mon F508del mu­ta­tion. Ver­tex’s first-ever ap­proved CF drug is Ka­ly­de­co. Its triplet reg­i­men, Trikaf­ta, which is de­signed to treat 90% of all CF pa­tients, was ap­proved by the FDA a spec­tac­u­lar five months ahead of its ex­pect­ed de­ci­sion date in Oc­to­ber.

“When a man­u­fac­tur­er has a mo­nop­oly on treat­ments and is aware that in­sur­ers will be un­able to refuse cov­er­age, the lack of usu­al coun­ter­bal­anc­ing forces can lead to ex­ces­sive prices. Pa­tients who re­ceive the treat­ments will ben­e­fit, but un­aligned prices will cause sig­nif­i­cant neg­a­tive health con­se­quences for many un­seen in­di­vid­u­als – those through­out so­ci­ety who will ex­pe­ri­ence fi­nan­cial tox­i­c­i­ty and may have to de­lay care, forego care, or even aban­don in­sur­ance as their out of pock­et costs and pre­mi­ums are dri­ven up­ward,” said Rind.

There was no doubt that all three drugs, most no­tably Trikaf­ta, of­fer a clin­i­cal ben­e­fit over stan­dard sup­port­ive CF care — ICER’s analy­sis sug­gest­ed that dis­counts of up to 77% would be im­per­a­tive to align prices with the drugs’ clin­i­cal val­ue.

The in­sti­tute worked up a health ben­e­fit price bench­mark (HBPB) — a price range in­di­cat­ing the high­est price a man­u­fac­tur­er should charge for a treat­ment, based on the amount of im­prove­ment in over­all health pa­tients achieve on that ther­a­py. Each of the four ther­a­pies, ac­cord­ing to this analy­sis, re­quires a sub­stan­tial dis­count, with­out which Ver­tex risks caus­ing “dis­pro­por­tion­ate­ly greater loss­es in health among oth­er pa­tients in the health sys­tem due to ris­ing over­all costs of health care and health in­sur­ance.”

Al­though these drugs were de­vel­oped with sig­nif­i­cant fi­nan­cial and sci­en­tif­ic sup­port from the Cys­tic Fi­bro­sis Foun­da­tion, a rep­re­sen­ta­tive from the group sug­gest­ed that it was not in­clud­ed in Ver­tex’s dis­cus­sions around how the prod­ucts would be priced, ICER said.

Akin to NICE in the UK, ICER is an in­de­pen­dent body that an­a­lyzes the cost-ef­fec­tive­ness of drugs and oth­er med­ical ser­vices in the Unit­ed States. Un­like NICE, though, ICER is not gov­ern­ment-af­fil­i­at­ed, but its de­ter­mi­na­tions are in­creas­ing­ly gain­ing trac­tion with pay­ers and pol­i­cy­mak­ers. Man­u­fac­tur­ers fre­quent­ly at­tack the method­olo­gies the in­sti­tute em­ploys in its analy­ses.

So­cial im­age: Resh­ma Ke­wal­ra­mani, Ver­tex CEO via YouTube

When the FDA slapped a rejection on Kala Pharma’s dry eye drug last August, the biotech’s execs promised investors that a third Phase III study — they had already started at that point — would reverse their fortune.

Today they made good on that promise, clinching an approval for Eysuvis, an ocular corticosteroid being positioned as a first-line, short term treatment of dry eye disease.

Boasting a technology invented by Bob Langer out of MIT, Eysuvis is a corticosteroid, loteprednol etabonate, delivered by mucus-penetrating particles. It promises to enhance penetration into target tissue on the ocular surface, achieving an effect quicker than systemic corticosteroids and stronger than over-the-counter eye drops.

A couple years after licensing Novimmune’s emapalumab and turning around a quick FDA OK, Stockholm-based Sobi is betting up to $1.2 billion for rights to another rare disease drug.

The company is shelling out $250 million upfront and adding up to $915 million in milestones for rights to develop and commercialize Apellis Pharmaceuticals’ drug pegcetacoplan outside the US. Together, the companies will see the systemic C3 therapy through five registrational trials in hematology, nephrology and neurology.

The last four years have seen a sudden explosion in treatments for spinal muscular atrophy, a neurodegenerative condition that once led patients — often young ones — with a grim prognosis and no options. The prognosis still isn’t rosy, but now there are three FDA-approved options, enough to make the choice of one difficult.

Now a fourth potential option has entered the mix. Today, Scholar Rock announced the results from a proof-of-concept testing their SMA drug by itself and in combination with Ionis’ Spinraza, showing that all patient cohorts improved on standard scales used for measuring motor function in people with SMA.